Literature DB >> 22825757

Role of the p38 MAPK signaling pathway in mediating interleukin-28A-induced migration of UMUC-3 cells.

Se-Jung Lee1, Wun-Jae Kim, Sung-Kwon Moon.   

Abstract

Although interleukin-28A (IL-28A) is believed to have an antiviral effect, its role in tumor migration requires further examination. The present study was intended to verify the effect of IL-28A on the migration of UMUC-3 bladder cancer cells. IL-28A and its receptor IL-28AR1 mRNA were detected in UMUC-3 cells. Although exogenous IL-28A showed no effect on cell proliferation, a wound-healing migration assay showed that the migration of UMUC-3 cells was induced by IL-28A. Furthermore, treatment of the cells with IL-28A significantly promoted MMP-9 expression via binding activities of NF-κB and AP-1. IL-28A also induced the activation of p38 MAPK and Jak2-Stat2 signaling. Using the p38 MAPK inhibitor SB203580 and the dominant-negative plasmid DN-p38, we found evidence that the inhibition of p38 MAPK signaling suppressed the effects of IL-28A including wound-healing migration and MMP-9 expression by activation of NF-κB and AP-1 binding in UMUC-3 cells. However, Jak-2 inhibition by AG490 did not affect IL-28A-induced migration of UMUC-3 cells. Collectively, we suggest for the first time that the p38 MAPK pathway mediates IL-28A-induced cell migration through MMP-9 expression by activating NF-κB and AP-1 binding motifs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22825757     DOI: 10.3892/ijmm.2012.1064

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  24 in total

1.  Type III IFNs Are Commonly Induced by Bacteria-Sensing TLRs and Reinforce Epithelial Barriers during Infection.

Authors:  Charlotte Odendall; Andrew A Voak; Jonathan C Kagan
Journal:  J Immunol       Date:  2017-09-27       Impact factor: 5.422

Review 2.  Contribution of type III interferons to antiviral immunity: location, location, location.

Authors:  Sergei V Kotenko; Joan E Durbin
Journal:  J Biol Chem       Date:  2017-03-13       Impact factor: 5.157

Review 3.  Type III IFNs: Beyond antiviral protection.

Authors:  Sergei V Kotenko; Amariliz Rivera; Dane Parker; Joan E Durbin
Journal:  Semin Immunol       Date:  2019-06       Impact factor: 11.130

4.  Mechanisms of Innate Immune Activation by a Hybrid Alphavirus-Rhabdovirus Vaccine Platform.

Authors:  Anthony M Marchese; Carolina Chiale; Safiehkhatoon Moshkani; Michael D Robek
Journal:  J Interferon Cytokine Res       Date:  2019-10-18       Impact factor: 2.607

Review 5.  Shared and Distinct Functions of Type I and Type III Interferons.

Authors:  Helen M Lazear; John W Schoggins; Michael S Diamond
Journal:  Immunity       Date:  2019-04-16       Impact factor: 31.745

Review 6.  The unique regulation and functions of type III interferons in antiviral immunity.

Authors:  Charlotte Odendall; Jonathan C Kagan
Journal:  Curr Opin Virol       Date:  2015-03-12       Impact factor: 7.090

7.  MicroRNA-524-5p suppresses the growth and invasive abilities of gastric cancer cells.

Authors:  Guang-Hui Liu; Yuan-Hua Liu; Zhen Yang; A-Li Zhu; Chun-Lin Zhao
Journal:  Oncol Lett       Date:  2016-01-26       Impact factor: 2.967

Review 8.  Interferon-λ orchestrates innate and adaptive mucosal immune responses.

Authors:  Liang Ye; Daniel Schnepf; Peter Staeheli
Journal:  Nat Rev Immunol       Date:  2019-06-14       Impact factor: 53.106

9.  Selective Janus kinase inhibition preserves interferon-λ-mediated antiviral responses.

Authors:  Daniel Schnepf; Stefania Crotta; Thiprampai Thamamongood; Megan Stanifer; Laura Polcik; Annette Ohnemus; Juliane Vier; Celia Jakob; Miriam Llorian; Hans Henrik Gad; Rune Hartmann; Birgit Strobl; Susanne Kirschnek; Steeve Boulant; Martin Schwemmle; Andreas Wack; Peter Staeheli
Journal:  Sci Immunol       Date:  2021-05-14

10.  Critical role of interferons in gastrointestinal injury repair.

Authors:  Constance McElrath; Vanessa Espinosa; Jian-Da Lin; Jianya Peng; Raghavendra Sridhar; Orchi Dutta; Hsiang-Chi Tseng; Sergey V Smirnov; Heidi Risman; Marvin J Sandoval; Viralkumar Davra; Yun-Juan Chang; Brian P Pollack; Raymond B Birge; Mark Galan; Amariliz Rivera; Joan E Durbin; Sergei V Kotenko
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.